Search

for
Search:

Research

5 / 910 results

Baricitinib Achieved Complete or Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials

research Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials

January 2025 in “SKIN The Journal of Cutaneous Medicine”

In this analysis of the BRAVE-AA trials, a significant number of patients with severe alopecia areata treated with baricitinib reached complete or nearly complete scalp coverage (SALT score ≤10 or ≤5) over 52 weeks, particularly among those with less severe baseline characteristics.

research Proteasome Inhibitors: An Expanding Army Attacking a Unique Target

474 citations , January 2012 in “Chemistry & biology”

This review discusses the discovery and potential therapeutic uses of proteasome inhibitors across various diseases, including cancer and autoimmune conditions, but does not present new clinical data.

research Overexpression of hypoxia-inducible factor-1α in hidradenitis suppurativa: the link between deviated immunity and metabolism

5 citations , March 2023 in “Archives of dermatological research”

This study found that hidradenitis suppurativa is associated with increased serum levels of hypoxia-inducible factor-1α, suggesting its role in the disease's pathogenesis and as a treatment target.

Efficacy And Safety Of Baricitinib Treatment In Alopecia Areata: A Retrospective Analysis

research Az alopecia areata kezelésében alkalmazott baricitinib hatásosságának és biztonságosságának retrospektív vizsgálata = Efficacy and safety of baricitinib treatment in alopecia areata:a retrospective analysis

January 2025 in “Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)”

In this study, baricitinib was found to be effective and safe for treating severe alopecia areata, with significant hair regrowth observed in many patients by the third month of therapy and continued improvement by the twelfth month, despite mostly mild adverse events.

research Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib

October 2025 in “Journal of Clinical Medicine”

This study found that in patients with severe alopecia areata, those who responded early to baricitinib treatment typically had a lower baseline Severity of Alopecia Tool score, shorter disease duration, and higher erythrocyte sedimentation rate, suggesting these factors may predict therapeutic success.

View more "20s core" in research →

Community Join

5 / 846 results

community I hate hairloss to my core, Fuck this shit

in Update 192 upvotes 8 months ago

The user is frustrated with hair loss, having switched from topical minoxidil and finasteride to dutasteride and oral minoxidil without seeing improvements. They are considering a hair transplant and are advised to continue the current treatment and explore therapy or lifestyle changes.

community Quit finasteride after 15+ years

972 upvotes 1 year ago

A user stopped finasteride after 15 years due to severe side effects, which improved after quitting. They maintained most of their hair and are considering alternatives like topical treatments or RU58841.

community Did George Clooney did a hair transplant?

2609 upvotes 10 months ago

George Clooney likely had a hair transplant, as many Hollywood actors do to maintain their appearance. Treatments like finasteride and hair transplants are common among celebrities to combat hair loss.

community Popular hair loss drug linked to higher suicide risk: compared to non-users, finasteride (Proscar/ Propecia) users have a markedly increased risk of depression, anxiety, and suicidal thoughts. Over 30 years of observation, 19,320 suicides were expected.

494 upvotes 11 months ago

Finasteride users may have an increased risk of depression, anxiety, and suicidal thoughts, though some attribute these issues to hair loss itself. The link between finasteride and mental health effects is debated, with varying user experiences.

community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

124 upvotes 2 years ago

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

View more "20s core" in community →